Bictegravir 10-day Dose-Ranging Monotherapy
GS-141-1219
Bictegravir 10-day Dose-Ranging Monotherapy
GS-141-1219: Design

**GS-141-1219: Study Design**

**Background**: Randomized, double-blind, dose-ranging, placebo-controlled, 10-day, phase 1b study to evaluate antiviral activity, safety, and pharmacokinetics of the INSTI bictegravir in adults with HIV

**Inclusion Criteria (n = 20)**
- Antiretroviral-naïve or
- Antiretroviral-experienced but INSTI-naïve
- Age: between 18 and 65
- CD4 >200 cells/mm³
- HIV RNA between 10,000 and 400,000 copies/mL

**Treatment Arms**
- Bictegravir: 5, 25, 50, or 100 mg daily
- Placebo: daily

- **Bictegravir: 5 mg QD**
  (n = 4)

- **Bictegravir: 25 mg QD**
  (n = 4)

- **Bictegravir: 50 mg QD**
  (n = 4)

- **Bictegravir: 100 mg QD**
  (n = 4)

- **Placebo**
  (n = 4)

Bictegravir 10-day Dose-Ranging Monotherapy GS-141-1219: Results

Baseline to Day 11: Change in Baseline HIV RNA Level

Baseline to Day 11: Change in Baseline HIV RNA Level

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.